b*********3
发帖数: 1709 | 1 【 以下文字转载自 Military 讨论区 】
发信人: beijingren3 (), 信区: Military
标 题: 英国：冠状病毒的专利已于2015年申请并于2018年获得授权。
发信站: BBS 未名空间站 (Thu Jan 23 09:24:33 2020, 美东)
该专利的受让人是英国以外的政府资助的Pirbright研究所。
他们的一些主要资助者是世界卫生组织和比尔和梅琳达·盖茨基金会。
https://patents.justia.com/patent/10130701
Coronavirus
Jul 23, 2015 - THE PIRBRIGHT INSTITUTE
The present invention provides a live, attenuated coronavirus comprising a
variant replicase gene encoding polyproteins comprising a mutation in one or
more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The
coronavirus may be used as a vaccine for treating and/or preventing a
disease, such as infectious bronchitis, in a subject.
Description
FIELD OF THE INVENTION
The present invention relates to an attenuated coronavirus comprising a
variant replicase gene, which causes the virus to have reduced pathogenicity
. The present invention also relates to the use of such a coronavirus in a
vaccine to prevent and/or treat a disease.
BACKGROUND TO THE INVENTION
Avian infectious bronchitis virus (IBV), the aetiological agent of
infectious bronchitis (IB), is a highly infectious and contagious pathogen
of domestic fowl that replicates primarily in the respiratory tract but also
in epithelial cells of the gut, kidney and oviduct. IBV is a member of the
Order Nidovirales, Family Coronaviridae, Subfamily Corona virinae and Genus
Gammacoronavirus; genetically very similar coronaviruses cause disease in
turkeys, guinea fowl and pheasants.
Clinical signs of IB include sneezing, tracheal rales, nasal discharge and
wheezing. Meat-type birds have reduced weight gain, whilst egg-laying birds
lay fewer eggs and produce poor quality eggs. The respiratory infection
predisposes chickens to secondary bacterial infections which can be fatal in
chicks. The virus can also cause permanent damage to the oviduct,
especially in chicks, leading to reduced egg production and quality; and
kidney, sometimes leading to kidney disease which can be fatal.
IBV has been reported to be responsible for more economic loss to the
poultry industry than any other infectious disease. Although live attenuated
vaccines and inactivated vaccines are universally used in the control of
IBV, the protection gained by use of vaccination can be lost either due to
vaccine breakdown or the introduction of a new IBV serotype that is not
related to the vaccine used, posing a risk to the poultry industry.
Further, there is a need in the industry to develop vaccines which are
suitable for use in ovo, in order to improve the efficiency and cost-
effectiveness of vaccination programmes. A major challenge associated with
in ovo vaccination is that the virus must be capable of replicating in the
presence of maternally-derived antibodies against the virus, without being
pathogenic to the embryo. Current IBV vaccines are derived following
multiple passage in embryonated eggs, this results in viruses with reduced
pathogenicity for chickens, so that they can be used as live attenuated
vaccines. However such viruses almost always show an increased virulence to
embryos and therefore cannot be used for in ova vaccination as they cause
reduced hatchability. A 70% reduction in hatchability is seen in some cases.
Attenuation following multiple passage in embryonated eggs also suffers from
other disadvantages. It is an empirical method, as attenuation of the
viruses is random and will differ every time the virus is passaged, so
passage of the same virus through a different series of eggs for attenuation
purposes will lead to a different set of mutations leading to attenuation.
There are also efficacy problems associated with the process: some mutations
will affect the replication of the virus and some of the mutations may make
the virus too attenuated. Mutations can also occur in the S gene which may
also affect immunogenicity so that the desired immune response is affected
and the potential vaccine may not protect against the required serotype. In
addition there are problems associated with reversion to virulence and
stability of vaccines.
It is important that new and safer vaccines are developed for the control of
IBV. Thus there is a need for IBV vaccines which are not associated with
these issues, in particular vaccines which may be used for in ovo
vaccination.
SUMMARY OF ASPECTS OF THE INVENTION | b*********3
发帖数: 1709 | 2 How interesting that the CDC has a patent on the human coronavirus...
https://patents.google.com/patent/US7220852 | b*********3
发帖数: 1709 | 3 The Coronavirus began field testing in 2015 and was granted a patent in 2018
. See attached video.
https://www.youtube.com/watch?v=q4idy-1688o
Number of reported cases is total fiction; number closer to 6,000 and
doubling every 48 hours. Yes, it's airborne.
In 1899 the Bayer Home Remedies handbook listed the following natural
product as the best way to deal with viruses;
https://www.amazon.com/gp/product/B00KE62DWS/ref=ppx_yo_dt_b_search_asin_
image?ie=UTF8&psc=1
I take 1 teaspoon every 7-10 days. Why? Because I have dogs and when dogs
roll in poop or on something dead, and you touch their fur, you'll pick up
parasites, i.e. worm larvae | b*********3
发帖数: 1709 | 4 So the Coronavirus was patented a fews back by a company that gets most of
its funding from the Melinda and Bill Gates foundation...
Anyone else see a problem with this?
not long ago some Chinese National was busted trying to take vials of bio-
medical substances out of Logan to China? Connection?
They, MSM, said it was Cancer research... sure I believe everything the MSM
says, NOT! | k*****a
发帖数: 7389 | | d********a
发帖数: 9567 | 6 北京O人找不到下嘴的角度了
到底是黑美还是舔美，组织上没交待清楚吗？ |
|
